Navigation Links
Astex, CRT and the Institute of Cancer Research announce epigenetic drug discovery collaboration
Date:9/7/2012

Astex Pharmaceuticals, Inc (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.

The collaboration combines Astex's world-renowned fragment-based drug discovery platform and epigenetic* drug development experience with the expertise in blood cancer biology at The Institute of Cancer Research (ICR) and proven success in drug discovery at the Cancer Research UK Cancer Therapeutics Unit at the ICR.

Dysregulated epigenetic mechanisms are now understood to underlie a variety of cancer types, and have been successfully targeted by the first generation of epigenetic anticancer drugs**. In some cases, specific epigenetic mutational events can be linked to disease etiology, providing an opportunity to develop highly targeted personalised medicines and associated companion diagnostics that will ultimately improve survival and reduce side effects.

"We are delighted to be entering into this new collaboration with the ICR and CRT on a key epigenetics target," said Harren Jhoti, PhD, president of Astex Pharmaceuticals. "This new partnership builds on the highly successful collaboration which Astex entered into with the ICR and CRT in 2003 on another cancer target, PKB/Akt. That collaboration led to the discovery of two clinical candidates, the first of which, AZD5363, was taken into Phase I by our partner AstraZeneca in early 2011 and the second of which, AT13148, is being prepared to be taken into Phase 1 under our development partnership with Cancer Research UK. "

Professor Paul Workman, director of the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, said: "ICR scientists are pioneers at unravelling blood cancer drug targets, which others have considered challenging to drug effectively. We have a very strong track record of designing drugs to attack challenging biological targets and bringing them into clinical trial, and given Astex's complementary expertise, we are very excited about the potential of this collaboration."

Dr Phil L'Huillier, director of business management at CRT, said: "Putting in place this collaboration between the Cancer Research UK-funded drug discovery team at the ICR and Astex provides a powerful route to identify drug candidates for this promising new target.

"The deal will ensure that the research programme benefits from the necessary investment to progress the research to its full potential while building on the validation and assay development work that has been carried out at the ICR and funded by Cancer Research UK and others.

"We hope that this research will lead to the development of new drugs to ultimately improve survival for cancer patients."


'/>"/>
Contact: Jane Bunce
jane.bunce@icr.ac.uk
44-207-153-5106
Institute of Cancer Research
Source:Eurekalert

Related medicine news :

1. David H. Koch donates $10 million to Mount Sinais Jaffe Food Allergy Institute
2. Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder
3. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
4. A North American first at the Montreal Heart Institute
5. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
6. Data release from the Allen Institute for Brain Science expands online atlas offerings
7. Los Robles Hospital’s Annual Health Fair Attended by Khanna Institute
8. Patient Experience Regional Roundtables Announced by The Beryl Institute
9. Stanford Woods Institute for the Environment announces 2012 Environmental Venture Project awards
10. Aetna Institute Designates RSC New England Center of Excellence
11. To tackle health cares thorniest problems, 400 health researchers form new U-M-based institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... Seattle, Washington (PRWEB) , ... April 24, 2017 , ... ... T-Fal OptiGrill, Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill ... than perhaps any other marketer in the last 25 years. , Now, due to ...
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class designers ... to bring their novel lifesaving device for the everyday use of parents worldwide. ... specially designed to read a child’s vital signs, and detect unusual symptoms or ...
(Date:4/24/2017)... ... April 24, 2017 , ... According to ... deaths now claim the lives of 62 Americans each day.(1) Yet since 2011, ... manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus Medical Detox ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, ... HIV because it is not known to have significant interactions with antiretroviral therapy ... both lower cholesterol levels and dampen inflammation in the bloodstream. , While lowering ...
(Date:4/24/2017)... FOREST KNOLLS, Calif. (PRWEB) , ... April 24, 2017 , ... ... and health topics, but she has not found any of them to be very ... weekly actions to slowly and easily make changes in their health. It prompted her ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical ... patients in Nashville , Tennesse have ... Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. The ... provide long-term reflux control by restoring normal function to ... 65 million people in the United States ...
(Date:4/19/2017)... BOSTON , April 19, 2017  New research provides ... with advanced Parkinson,s, according to a study released today that ... 69th Annual Meeting in Boston , ... comes to the treatment of Parkinson,s disease, the oral drug ... of life and longevity. But as the disease progresses, the ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... and Gynecology markets with innovative and proprietary products, will ... 31, 2017 after the market close on Tuesday, May ... a conference call and webcast to discuss its financial ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
Breaking Medicine Technology: